Scienmag
DECEMBER 3, 2020
A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.
Roots Analysis
MARCH 16, 2023
The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.
Drug Discovery World
NOVEMBER 9, 2023
Advances in discovery and engineering of antibodies for non-cancer targets This session will feature a range of presentations which include: Joshua Tan, PhD, Chief, Antibody Biology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, on: ‘Discovery of broadley-neutralising antibodies against Coronaviruses’.
Expert insights. Personalized for you.
40 
Let's personalize your content